PF 07872412
Alternative Names: PF-07872412Latest Information Update: 23 Aug 2024
At a glance
- Originator Pfizer
- Class Conjugate vaccines; Pneumococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Pneumococcal infections
Most Recent Events
- 31 Jul 2024 Phase-II clinical trials in Pneumococcal infections (Prevention) (Unspecified) (Pfizer pipeline, July 2024)
- 13 Feb 2024 Phase-I clinical trials in Pneumococcal infections (Prevention) (Parenteral), prior to February 2024 (Pfizer pipeline, February 2024)
- 13 Feb 2024 PF 07872412 receives Fast Track designation for Pneumococcal infections [Parenteral] (Prevention) in USA, prior to February 2024 (Pfizer pipeline, February 2024)